Plunkett Research Online: Kyverna Therapeutics Inc

KYVERNA THERAPEUTICS INC (KYTX:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is.....



Kyverna Therapeutics Inc
Ticker: KYTX
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 510 925-2492
Fax:
Address: 5980 Horton Street
Suite 550
Emeryville, CA 94608 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology
Biotechnology
Healthcare

Ranks not available
Contacts Description
Peter MaagCEO/Director
Ryan JonesCFO
See More
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is.....See More See More

Auditor: BDO USA, P.C
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: